Brian S. Lucas
Fulcrum Therapeutics (United States)(US)
Publications by Year
Research Areas
Synthetic Organic Chemistry Methods, Asymmetric Synthesis and Catalysis, Chemical Synthesis and Analysis, Heat shock proteins research, Epigenetics and DNA Methylation
Most-Cited Works
- → AMG 176, a Selective MCL1 Inhibitor, Is Effective in Hematologic Cancer Models Alone and in Combination with Established Therapies(2018)409 cited
- → Discovery of AMG 232, a Potent, Selective, and Orally Bioavailable MDM2–p53 Inhibitor in Clinical Development(2014)291 cited
- → A small molecule designed to bind to the adenine nucleotide pocket of Hsp90 causes Her2 degradation and the growth arrest and differentiation of breast cancer cells(2001)284 cited
- → Development of a Purine-Scaffold Novel Class of Hsp90 Binders that Inhibit the Proliferation of Cancer Cells and Induce the Degradation of Her2 Tyrosine Kinase(2002)194 cited
- → Targeting Wide-Range Oncogenic Transformation via PU24FCl, a Specific Inhibitor of Tumor Hsp90(2004)169 cited
- → Development of Purine-Scaffold Small Molecule Inhibitors of Hsp90(2003)105 cited
- → Discovery and in Vivo Evaluation of (S)-N-(1-(7-Fluoro-2-(pyridin-2-yl)quinolin-3-yl)ethyl)-9H-purin-6-amine (AMG319) and Related PI3Kδ Inhibitors for Inflammation and Autoimmune Disease(2014)85 cited
- → Total Synthesis of Phorboxazole B(2006)65 cited
- → An Expeditious Synthesis of the MDM2–p53 Inhibitor AM-8553(2012)44 cited
- → Design, synthesis and identification of novel, orally bioavailable non-covalent Nrf2 activators(2019)42 cited